Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 2, Subprotocol of DAY101 Monotherapy for Patients With Recurrent, Progressive, or Refractory Solid Tumors With MAPK Pathway Aberrations

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04985604
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:13.460561+00:00
Published At
2025-10-02T00:00:00+00:00
Record Updated At
2025-10-02
Results Posted At
2025-10-02
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Melanoma", "Solid Tumor", "CRAF Gene Amplification", "RAF1 Gene Amplification", "BRAF Gene Fusion", "BRAF Fusion", "CRAF Gene Fusion", "CRAF Fusion", "RAF1 Gene Fusion", "RAF1 Fusion", "Thyroid Cancer, Papillary", "Spitzoid Melanoma", "Pilocytic Astrocytoma", "Pilocytic Astrocytoma, Adult", "Non Small Cell Lung Cancer", "Non-Small Cell Adenocarcinoma", "Colorectal Cancer", "Pancreatic Acinar Carcinoma", "Spitzoid Malignant Melanoma", "Bladder Cancer", "Bladder Urothelial Carcinoma", "MAP Kinase Family Gene Mutation", "RAF Mutation"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-10-02"
protocolSection.identificationModule.nctId
"NCT04985604"
protocolSection.identificationModule.officialTitle
"A Phase 2, Subprotocol of DAY101 Monotherapy for Patients With Recurrent, Progressive, or Refractory Solid Tumors With MAPK Pathway Aberrations"
protocolSection.statusModule.overallStatus
"TERMINATED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2025-10-02"

Study condition terms

  • Melanoma (protocolSection.conditionsModule.conditions)
  • Solid Tumor (protocolSection.conditionsModule.conditions)
  • CRAF Gene Amplification (protocolSection.conditionsModule.conditions)
  • RAF1 Gene Amplification (protocolSection.conditionsModule.conditions)
  • BRAF Gene Fusion (protocolSection.conditionsModule.conditions)
  • BRAF Fusion (protocolSection.conditionsModule.conditions)
  • CRAF Gene Fusion (protocolSection.conditionsModule.conditions)
  • CRAF Fusion (protocolSection.conditionsModule.conditions)
  • RAF1 Gene Fusion (protocolSection.conditionsModule.conditions)
  • RAF1 Fusion (protocolSection.conditionsModule.conditions)
  • Thyroid Cancer, Papillary (protocolSection.conditionsModule.conditions)
  • Spitzoid Melanoma (protocolSection.conditionsModule.conditions)
  • Pilocytic Astrocytoma (protocolSection.conditionsModule.conditions)
  • Pilocytic Astrocytoma, Adult (protocolSection.conditionsModule.conditions)
  • Non Small Cell Lung Cancer (protocolSection.conditionsModule.conditions)
  • Non-Small Cell Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Colorectal Cancer (protocolSection.conditionsModule.conditions)
  • Pancreatic Acinar Carcinoma (protocolSection.conditionsModule.conditions)
  • Spitzoid Malignant Melanoma (protocolSection.conditionsModule.conditions)
  • Bladder Cancer (protocolSection.conditionsModule.conditions)
  • Bladder Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
  • MAP Kinase Family Gene Mutation (protocolSection.conditionsModule.conditions)
  • RAF Mutation (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.